Samsung Biologics Co.,Ltd.

Equities

A207940

KR7207940008

Pharmaceuticals

End-of-day quote Korea S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
833,000 KRW -0.36% Intraday chart for Samsung Biologics Co.,Ltd. -2.80% +9.61%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Samsung Life Science Fund Invests in Biologics Developer MT
Samsung Group Initiates Open Hiring Drive for New Talent Acquisition MT
South Korean Shares Close Higher After US Fed Chief Hints at Rate Cuts; Samsung Biologics Adds 1% MT
Samsung Biologics Strikes $353 Million Deal with Belgium's UCB MT
South Korean Shares Dip on Tech, Pharma Losses; Celltrion Sheds 5% on Lackluster Q4 Earnings MT
Samsung Biologics Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Samsung Biologics Collaborates with LegoChem Biosciences on ADC Development and Manufacturing MT
Samsung Biologics's Q4 Net Income Declines MT
Samsung Biologics Subsidiary Secures Ministry Approval for Soliris Biosimilar MT
Samsung C&T Inks Deal with US-Based Flagship Pioneering for Bio Startup Investment MT
Rapid Micro Biosystems Shares Rise After Samsung Biologics Partnership DJ
South Korean shares fall for second day after US Fed minutes RE
S.Korean shares fall after Fed minutes; biopharma leads declines RE
S.Korean shares hit 19-month high on biopharma, e-commerce boost RE
Samsung Bioepis Enters Joint Research Pact with IntoCell MT
South Korean shares hit over two-month high on lower US bond yields RE
Samsung Biologics Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Samsung Biologics' Net Profit Jumps 86% in Q3 MT
Samsung Biologics and Kurma Partners Announce Strategic Partnership for Development and Manufacturing of Biologics for Kurma's Portfolio Companies CI
South Korean Shares Close Higher as Investors Eye US Payrolls Data; Samsung Biologics Adds 1% MT
Samsung Biologics Boosts 2023 Revenue Projection Amid Surging Demand MT
S.Korean shares climb ahead of US payrolls data; still down for week RE
South Korean shares end over 2% lower as surging US bond yields weigh RE
Samsung Biologics Signs $242 Million Drug Manufacturing Deal MT
South Korean shares post worst day in a month as chipmakers drop RE
Chart Samsung Biologics Co.,Ltd.
More charts
Samsung Biologics Co Ltd is a Korea-based company primarily engaged in development, manufacture and distribution of biological products. The Company, as a contract manufacturing organization (CMO), mainly develops and manufactures antibody drugs used for treatment of cancer, autoimmune disease, diabetes and chronic diseases. It also provides cell line development and process development services. The Company distributes its products in domestic and overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
833,000 KRW
Average target price
1,035,455 KRW
Spread / Average Target
+24.30%
Consensus
  1. Stock
  2. Equities
  3. Stock Samsung Biologics Co.,Ltd. - Korea S.E.
  4. News Samsung Biologics Co.,Ltd.
  5. Market Chatter: Samsung Bioepis' Biosimilar Sales Globally Surge 30% in H1